Amarin Corp Plc (AMRN)

[Number sleven]

JRoon, They all do it. Some less overtly than others. It is how generic companies have exploited the "skinny label" since enactment of Hatch Waxman. They all avoid clearly defining the indication that they have been approved for. They release a product as a generic equivalent. The intent is that it will be substituted for all indications. Amarin is using the ruling in GSK v Teva to support this suit. Soon we should see a ruling from the court of appeals. If that ruling has any wording about the Hikma failure to define it's indication, it opens up other generic companies to inducement.
Sleven,